Overview

A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma

Status:
Not yet recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

The goal of this phase I interventional study is to determine the safety and feasibility of the proposed investigational (neo-)adjuvant treatment regimen in patients with resectable reccurent glioblastoma. Participants will: - receive neo-adjuvant administration of intravenous immunotherapy - followed by a maximal safe neurosurgical resection - afterwards, immunotherapy will be injected into the brain tissue - followed by insertion of an Ommaya reservoir - postoperatively, administration of immunotherapy will be continued

Phase:

Phase 1

Details

Lead Sponsor:

Universitair Ziekenhuis Brussel

Treatments:

Nivolumab